From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

被引：23

作者：

Anker, Jonathan ^{[1
]}

Miller, Justin ^{[2
]}

Taylor, Nicole ^{[2
]}

Kyprianou, Natasha ^{[3
,4
,5
]}

Tsao, Che-Kai ^{[2
,3
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Internal Med, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Pathol & Mol & Cell Based Med, New York, NY 10029 USA

[5] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA

来源：

CELLS | 2021年 / 10卷 / 11期

关键词：

renal cell carcinoma; tumor microenvironment; immunology; immunotherapy; REGULATORY T-CELLS; PHASE I/II TRIAL; PATIENTS PTS; CHECKPOINT INHIBITORS; ADJUVANT SUNITINIB; SUPPRESSOR-CELLS; 1ST-LINE THERAPY; PROGNOSTIC VALUE; CTLA-4; BLOCKADE; DOSE-ESCALATION;

D O I：

10.3390/cells10113231

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.

引用

页数：31

共 213 条

[11] Sarcomatoid renal cell carcinoma: biology, natural history and management [J].

Blum, Kyle A. ;

Gupta, Sounak ;

Tickoo, Satish K. ;

Chan, Timothy A. ;

Russo, Paul ;

Motzer, Robert J. ;

Karam, Jose A. ;

Hakimi, A. Ari .

NATURE REVIEWS UROLOGY, 2020, 17 (12) :659-678

[12] 36-kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in Clear Cell Renal Cell Carcinoma Cells [J].

Bombelli, Silvia ;

Torsello, Barbara ;

De Marco, Sofia ;

Lucarelli, Giuseppe ;

Cifola, Ingrid ;

Grasselli, Chiara ;

Strada, Guido ;

Bovo, Giorgio ;

Perego, Roberto A. ;

Bianchi, Cristina .

AMERICAN JOURNAL OF PATHOLOGY, 2020, 190 (11) :2317-2326

[13]

Brannon A Rose, 2010, Genes Cancer, V1, P152

[14] Progressive immune dysfunction with advancing disease stage in renal cell carcinoma [J].

Braun, David A. ;

Street, Kelly ;

Burke, Kelly P. ;

Cookmeyer, David L. ;

Denize, Thomas ;

Pedersen, Christina B. ;

Gohil, Satyen H. ;

Schindler, Nicholas ;

Pomerance, Lucas ;

Hirsch, Laure ;

Bakouny, Ziad ;

Hou, Yue ;

Forman, Juliet ;

Huang, Teddy ;

Li, Shuqiang ;

Cui, Ang ;

Keskin, Derin B. ;

Steinharter, John ;

Bouchard, Gabrielle ;

Sun, Maxine ;

Pimenta, Erica M. ;

Xu, Wenxin ;

Mahoney, Kathleen M. ;

McGregor, Bradley A. ;

Hirsch, Michelle S. ;

Chang, Steven L. ;

Livak, Kenneth J. ;

McDermott, David F. ;

Shukla, Sachet A. ;

Olsen, Lars R. ;

Signoretti, Sabina ;

Sharpe, Arlene H. ;

Irizarry, Rafael A. ;

Choueiri, Toni K. ;

Wu, Catherine J. .

CANCER CELL, 2021, 39 (05) :632-+

[15] Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma [J].

Braun, David A. ;

Hou, Yue ;

Bakouny, Ziad ;

Ficial, Miriam ;

Sant' Angelo, Miriam ;

Forman, Juliet ;

Ross-Macdonald, Petra ;

Berger, Ashton C. ;

Jegede, Opeyemi A. ;

Elagina, Liudmilla ;

Steinharter, John ;

Sun, Maxine ;

Wind-Rotolo, Megan ;

Pignon, Jean-Christophe ;

Cherniack, Andrew D. ;

Lichtenstein, Lee ;

Neuberg, Donna ;

Catalano, Paul ;

Freeman, Gordon J. ;

Sharpe, Arlene H. ;

McDermott, David F. ;

Van Allen, Eliezer M. ;

Signoretti, Sabina ;

Wu, Catherine J. ;

Shukla, Sachet A. ;

Choueiri, Toni K. .

NATURE MEDICINE, 2020, 26 (06) :909-+

[16] Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma [J].

Braun, David A. ;

Ishii, Yuko ;

Walsh, Alice M. ;

Van Allen, Eliezer M. ;

Wu, Catherine J. ;

Shukla, Sachet A. ;

Choueiri, Toni K. .

JAMA ONCOLOGY, 2019, 5 (11) :1631-1633

[17] The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer [J].

Bromwich, EJ ;

McArdle, PA ;

Canna, K ;

McMillan, DC ;

McNicol, AM ;

Brown, M ;

Aitchison, M .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1906-1908

[18] Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma [J].

Callea, Marcella ;

Albiges, Laurence ;

Gupta, Mamta ;

Cheng, Su-Chun ;

Genega, Elizabeth M. ;

Fay, Andre P. ;

Song, Jiaxi ;

Carvo, Ingrid ;

Bhatt, Rupal S. ;

Atkins, Michael B. ;

Hodi, F. Stephen ;

Choueiri, Toni K. ;

McDermott, David F. ;

Freeman, Gordon J. ;

Signoretti, Sabina .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) :1158-1164

[19] The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials [J].

Carretero-Gonzalez, Alberto ;

Lora, David ;

Martin Sobrino, Isabel ;

Saez Sanz, Irene ;

Bourlon, Maria T. ;

Anido Herranz, Urbano ;

Chanza, Nieves Martinez ;

Castellano, Daniel ;

de Velasco, Guillermo .

CANCERS, 2020, 12 (07) :1-16

[20] Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma [J].

Carril-Ajuria, Lucia ;

Santos, Maria ;

Maria Roldan-Romero, Juan ;

Rodriguez-Antona, Cristina ;

de Velasco, Guillermo .

CANCERS, 2020, 12 (01)

← 1 2 3 4 5 6 7 8 9 10 →